A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

(2017) A Bouillez et al.   ONCOGENE

Pharmacological and immunological targeting of tumor mesenchymalization

(2017) Justin M. David et al.   PHARMACOLOGY & THERAPEUTICS

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

(2016) Y. Lou et al.   CLINICAL CANCER RESEARCH

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

(2016) Sehui Kim et al.   HUMAN PATHOLOGY

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

(2016) RYOTA KURIMOTO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

(2016) Masaki Shimoji et al.   LUNG CANCER

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

(2016) Chan-Young Ock et al.   Oncotarget

The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

(2016) Lian Zhao et al.   Oncotarget

Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification

(2016) Ling Liu et al.   Scientific Reports

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance

(2016) Marije Baas et al.   eLife

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition

(2016) Justin M. David et al.   OncoImmunology

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

(2015) M. P. Mak et al.   CLINICAL CANCER RESEARCH

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

(2015) Luis Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells

(2015) Abdullah Alsuliman et al.   Molecular Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial–mesenchymal transition

(2015) M T Goswami et al.   ONCOGENE

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

(2015) Michael Lahn et al.   Drug Design Development and Therapy

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial-Mesenchymal Transition

(2014) D. H. Hamilton et al.   CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells

(2014) Shasha Song et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression

(2014) I Akalay et al.   ONCOGENE

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis

(2013) I. Akalay et al.   CANCER RESEARCH

Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis

(2013) D. G. Miguez et al.   JOURNAL OF CELL SCIENCE

An Autocrine Loop between TGF- 1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype

(2013) C. Larocca et al.   MOLECULAR CANCER THERAPEUTICS

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions

(2012) Helge Siemens et al.   CELL CYCLE

CCL2 is critical for immunosuppression to promote cancer metastasis

(2012) Chie Kudo-Saito et al.   CLINICAL & EXPERIMENTAL METASTASIS

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation

(2012) XIAO YAN NI et al.   ONCOLOGY REPORTS

MicroRNA-138 suppresses epithelial–mesenchymal transition in squamous cell carcinoma cell lines

(2011) Xiqiang Liu et al.   BIOCHEMICAL JOURNAL

An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition

(2011) Philip A. Gregory et al.   MOLECULAR BIOLOGY OF THE CELL

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells

(2009) Chie Kudo-Saito et al.   CANCER CELL

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION